Star Combo Pharma FCF Conversion
The FCF Conversion Rate (FCF/EBITDA) of Star Combo Pharma (S66.AX) as of Nov 7, 2026 is 208.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 220.02 % — a change of -5.25% (lower).
Get this data via API
Financial Data API
FCF Conversion
208.47 %
YoY
-5.25%
Last updated:
The Star Combo Pharma FCF Conversion history
3 Years
10 Years
25 Years
Max
| YEAR | FCF Conversion | YoY |
|---|---|---|
| 208.47 % | -5.25% | |
| 220.02 % | -193.52% | |
| -235.27 % | -1,205.59% | |
| 21.28 % | -97.94% | |
| 1,035.07 % | +1,077.04% | |
| 87.94 % | -91.93% | |
| 1,089.89 % | +192.97% | |
| 372.01 % | +260.46% | |
| 103.20 % | +151.47% | |
| 41.04 % | +399.07% | |
| 8.22 % | -101.20% | |
| -686.03 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Star Combo Pharma Stock analysis
Frequently Asked Questions about Star Combo Pharma stock
FCF Conversion Rate (FCF/EBITDA) of Star Combo Pharma is 208.47 % in 2026.
FCF Conversion Rate (FCF/EBITDA) of Star Combo Pharma changed from 220.02 % to 208.47 %, representing a -5.25% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Star Combo Pharma since 2006 – with annual values, charts, and detailed analysis.
FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.
A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Star Combo Pharma with sector peers and the industry average to assess whether it is attractive.
To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Star Combo Pharma
All Key Metrics — Star Combo Pharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth